FDA Approved: TAFINLAR — Original Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved TAFINLAR (dabrafenib) as an original application for the treatment of unresectable or metastatic malignant melanoma with BRAF V600E mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• TAFINLAR (DABRAFENIB)

Snippet

ORIG AP for TAFINLAR (DABRAFENIB)